{"title":"终末期青光眼患者严重角膜溃疡的临床特点和处理。","authors":"Yan Li, Xin Zhong, Di Ma","doi":"10.1007/s10792-025-03527-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To review the clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.</p><p><strong>Methods: </strong>Retrospectively reviewed the medical records of patients diagnosed with severe corneal ulcers who had a history of end-stage glaucoma, including demographic profiles, medical histories, clinical features, and treatments.</p><p><strong>Results: </strong>Thirty patients (30 eyes) were included. The median age at presentation was 73.00 years (interquartile range [IQR]: 64.25-77.25 years). The majority of patients were previously diagnosed with primary angle-closure glaucoma (11/30, 36.67%). Nineteen patients (63.33%) were still using antiglaucoma medications within 6 months before the onset of corneal ulcer. Visual acuity was already severely impaired in these patients before the onset of corneal ulcer. At last visit before the onset, 20 eyes (66.67%) had intraocular pressure (IOP) greater than 21 mmHg. Corneal perforation occurred in 13 eyes (43.33%). Eleven eyes (36.67%) underwent debridement of corneal ulcer and conjunctival flap covering surgery, while 13 eyes (43.33%) eventually underwent evisceration. Patients without corneal perforation had received a greater variety of surgical or laser treatments in the past compared to those with corneal perforation (P = 0.047). A significantly larger proportion of patients with corneal perforation underwent evisceration (9/13 vs 4/17, P = 0.012).</p><p><strong>Conclusion: </strong>Severe corneal ulcers in patients with end-stage glaucoma were characterized by advanced age, long-term use of topical antiglaucoma medications and poor IOP control. Nearly half of the patients lost their eyes. Active treatment of underlying diseases and careful attention to ocular surface condition are crucial in preventing corneal perforation and improving prognosis.</p>","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"173"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.\",\"authors\":\"Yan Li, Xin Zhong, Di Ma\",\"doi\":\"10.1007/s10792-025-03527-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To review the clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.</p><p><strong>Methods: </strong>Retrospectively reviewed the medical records of patients diagnosed with severe corneal ulcers who had a history of end-stage glaucoma, including demographic profiles, medical histories, clinical features, and treatments.</p><p><strong>Results: </strong>Thirty patients (30 eyes) were included. The median age at presentation was 73.00 years (interquartile range [IQR]: 64.25-77.25 years). The majority of patients were previously diagnosed with primary angle-closure glaucoma (11/30, 36.67%). Nineteen patients (63.33%) were still using antiglaucoma medications within 6 months before the onset of corneal ulcer. Visual acuity was already severely impaired in these patients before the onset of corneal ulcer. At last visit before the onset, 20 eyes (66.67%) had intraocular pressure (IOP) greater than 21 mmHg. Corneal perforation occurred in 13 eyes (43.33%). Eleven eyes (36.67%) underwent debridement of corneal ulcer and conjunctival flap covering surgery, while 13 eyes (43.33%) eventually underwent evisceration. Patients without corneal perforation had received a greater variety of surgical or laser treatments in the past compared to those with corneal perforation (P = 0.047). A significantly larger proportion of patients with corneal perforation underwent evisceration (9/13 vs 4/17, P = 0.012).</p><p><strong>Conclusion: </strong>Severe corneal ulcers in patients with end-stage glaucoma were characterized by advanced age, long-term use of topical antiglaucoma medications and poor IOP control. Nearly half of the patients lost their eyes. Active treatment of underlying diseases and careful attention to ocular surface condition are crucial in preventing corneal perforation and improving prognosis.</p>\",\"PeriodicalId\":14473,\"journal\":{\"name\":\"International Ophthalmology\",\"volume\":\"45 1\",\"pages\":\"173\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10792-025-03527-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03527-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:总结终末期青光眼患者严重角膜溃疡的临床特点和处理方法。方法:回顾性分析诊断为严重角膜溃疡并有终末期青光眼病史的患者的医疗记录,包括人口统计资料、病史、临床特征和治疗。结果:纳入患者30例(30只眼)。就诊时的中位年龄为73.00岁(四分位数间距[IQR]: 64.25-77.25岁)。多数患者既往诊断为原发性闭角型青光眼(11/30,36.67%)。19例患者(63.33%)在角膜溃疡发生前6个月内仍在使用抗青光眼药物。这些患者在发生角膜溃疡前视力已经严重受损。发病前最后一次访视时,20只眼(66.67%)眼压大于21 mmHg。角膜穿孔13眼(43.33%)。11只眼(36.67%)行角膜溃疡清创及结膜瓣覆盖手术,13只眼(43.33%)最终行摘除手术。与有角膜穿孔的患者相比,无角膜穿孔的患者过去接受过更多种类的手术或激光治疗(P = 0.047)。角膜穿孔患者的内脏切除比例明显更高(9/13 vs 4/17, P = 0.012)。结论:终末期青光眼患者严重角膜溃疡的特点是高龄、长期使用外用抗青光眼药物和IOP控制不佳。将近一半的病人失去了眼睛。积极治疗基础疾病和密切关注眼表状况是预防角膜穿孔和改善预后的关键。
Clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.
Purpose: To review the clinical characteristics and managements of severe corneal ulcers in patients with end-stage glaucoma.
Methods: Retrospectively reviewed the medical records of patients diagnosed with severe corneal ulcers who had a history of end-stage glaucoma, including demographic profiles, medical histories, clinical features, and treatments.
Results: Thirty patients (30 eyes) were included. The median age at presentation was 73.00 years (interquartile range [IQR]: 64.25-77.25 years). The majority of patients were previously diagnosed with primary angle-closure glaucoma (11/30, 36.67%). Nineteen patients (63.33%) were still using antiglaucoma medications within 6 months before the onset of corneal ulcer. Visual acuity was already severely impaired in these patients before the onset of corneal ulcer. At last visit before the onset, 20 eyes (66.67%) had intraocular pressure (IOP) greater than 21 mmHg. Corneal perforation occurred in 13 eyes (43.33%). Eleven eyes (36.67%) underwent debridement of corneal ulcer and conjunctival flap covering surgery, while 13 eyes (43.33%) eventually underwent evisceration. Patients without corneal perforation had received a greater variety of surgical or laser treatments in the past compared to those with corneal perforation (P = 0.047). A significantly larger proportion of patients with corneal perforation underwent evisceration (9/13 vs 4/17, P = 0.012).
Conclusion: Severe corneal ulcers in patients with end-stage glaucoma were characterized by advanced age, long-term use of topical antiglaucoma medications and poor IOP control. Nearly half of the patients lost their eyes. Active treatment of underlying diseases and careful attention to ocular surface condition are crucial in preventing corneal perforation and improving prognosis.
期刊介绍:
International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.